BisoT Tablets contain Bisoprolol Fumarate IP 2.5 mg/5 mg and Telmisartan IP 40 mg.

BisoT Tablets combine the cardioselective beta1-blocking action of Bisoprolol with the renin-angiotensin system inhibition of Telmisartan to provide effective once-daily control of Stage 1 and Stage 2 hypertension. Bisoprolol reduces heart rate, myocardial oxygen demand, cardiac output, and renin release, while Telmisartan selectively blocks angiotensin II at the AT1 receptor to reduce vasoconstriction and aldosterone secretion. The complementary mechanisms provide sustained blood pressure reduction and improved cardiovascular protection.

BisoT Tablets are indicated for the treatment of Stage 1 and Stage 2 hypertension.

Bisoprolol is a highly selective beta1-adrenergic receptor blocker with no intrinsic sympathomimetic or significant membrane-stabilizing activity. It reduces heart rate, cardiac output, myocardial oxygen consumption, and suppresses renin release, contributing to blood pressure reduction. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and the adrenal gland, thereby preventing vasoconstriction and aldosterone secretion, resulting in effective and sustained antihypertensive activity.

The recommended dosage is one tablet containing Bisoprolol Fumarate 2.5 mg/5 mg and Telmisartan 40 mg orally once daily, or as directed by the physician.

BisoT Tablets are contraindicated in patients with known hypersensitivity to Bisoprolol, Telmisartan, or any component of the formulation. They are also contraindicated in acute heart failure or episodes of decompensated heart failure requiring intravenous inotropic therapy, cardiogenic shock, second- or third-degree atrioventricular block, sick sinus syndrome, sinoatrial block, symptomatic bradycardia, symptomatic hypotension, severe bronchial asthma or severe chronic obstructive pulmonary disease, severe peripheral arterial occlusive disease, severe Raynaud's syndrome, untreated pheochromocytoma, and metabolic acidosis.